Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16102788 | 0.87 | CYP3A4 (0.60) | OPRM1OPRD1OPRK1LMNAALDH1A1 | |
| SCHEMBL18458736 | 0.85 | MEN1 (0.56) | LMNA | |
| SCHEMBL8970760 | 0.82 | KCNA3 (0.63) | KCNA3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL3724596 | 0.82 | OPRM1 (0.50) | OPRM1OPRD1OPRK1ALDH1A1 | |
| Pheneridine SCHEMBL1922392 | 0.80 | KCNA3 (0.86) | KCNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL20599253 | 0.80 | KCNH2 (0.50) | OPRM1 | |
| SCHEMBL21337310 | 0.79 | MEN1 (0.52) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3719268 | 0.79 | TSHR (0.46) | ALDH1A1 | |
| SCHEMBL11565095 | 0.77 | CA12 (0.59) | KCNA3OPRM1OPRD1OPRK1LMNA | |
| SCHEMBL10898506 | 0.76 | KCNH2 (0.71) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| EP-3328853-B1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-09-11 | — | — | EP | disclosed |
| EP-3328853-B1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-09-11 | — | — | EP | disclosed |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| WO-2017016669-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | KCNA3 335/4885OPRM1 1/4885OPRD1 2/4885 |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | KCNA3 335/4885OPRM1 1/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.